The Latest Innovations in the Drug Pipeline for Multiple Sclerosis
|
|
- Alan Harrell
- 6 years ago
- Views:
Transcription
1 CLINICAL SPECIAL FEATURE The Latest Innovations in the Drug Pipeline for Multiple Sclerosis Lea Radick and Stanton R. Mehr Am Health Drug Benefits. 2015;8(8): Disclosures are at end of text Several new medications are being investigated in late-phase studies for the treatment of patients with relapsing or progressive multiple sclerosis (MS). These agents represent a variety of mechanisms of action and provide not only lower relapse rates but also improvement in disabilities. The majority of investigational trials involve selective sphingosine-1-phosphate receptor 1 immunomodulators, such as laquinimod, ozanimod, ponesimod, and siponimod, in an effort to build on the success of fingolimod. Ocrelizumab is a CD20-positive B-cell targeting monoclonal antibody with a promising new mechanism of action. Ofatumumab is also a CD20 inhibitor. Daclizumab, an interleukin-2 inhibitor, has evidence of good efficacy but is associated with unfavorable side effects. Masitinib is a mast-cell inhibitor that also has shown efficacy in Alzheimer s disease and amyotrophic lateral sclerosis. Phase 3 trials for some of these agents will conclude in the next 12 months, and their manufacturers are expected to apply for US Food and Drug Administration approval soon thereafter. This review article summarizes data for newly approved and late-phase investigational agents for the treatment of patients with MS. A chronic disease of the central nervous system, multiple sclerosis (MS) is considered an immunemediated disorder in which the immune system attacks healthy neuronal tissue. MS affects more than 2.3 million people worldwide. Its most common symptoms include overwhelming fatigue, visual disturbances, altered sensation, and difficulties with mobility. Symptoms vary in type and severity from patient to patient. 1 Research and development in the treatment of MS has been rapid and active. For this review, the Clinical Trials.gov database was searched for phase 3 studies in MS that have been updated since December 1, Multiple sclerosis was the sole search term. Ninety-five results were returned, which covered approved agents being studied not only to treat patients with relapsing or progressive MS but also to address the symptoms of acute disease and its comorbidities. Moreover, the pipeline includes several new agents with different mechanisms of action. In addition to relapse prevention, an important focus of the newest classes of MS agents is to prevent disability. This article summarizes data for the agents most recently approved for treatment of patients with MS as well as data for the key investigational agents, which, if phase 3 results continue to show promise, may prove to be significant additions to the therapeutic armamentarium. Recently Approved Agents Peginterferon Beta-1a Approved by the US Food and Drug Administration Ms Radick is a medical writer based in Chicago, IL; Mr Mehr is President, SM Health Communications, Newtown, PA. (FDA) on August 15, 2014, and marketed as Plegridy by Biogen Idec, this compound is the pegylated follow-on version of Avonex (interferon beta-1a), which received FDA approval in 1996 for relapsing-remitting multiple sclerosis (RRMS). 2 Pegylation extends the half-life of the parent compound, permitting a less frequent dosing schedule than that of the unpegylated product, which requires a once-weekly injection. 3 The recommended dosage of peginterferon beta-1a is 125 μg every 14 days, by subcutaneous injection, with a prefilled pen-type syringe. 4 The FDA s approval of this drug was based on results of the ADVANCE study, a 2-year, randomized, phase 3, double-blind clinical trial in which efficacy and safety were evaluated. One-year ADVANCE study results indicate that after 48 weeks of treatment with peginterferon beta-1a, patients had a significantly reduced relapse rate compared with placebo. The drug might be an effective treatment for relapse- remitting multiple sclerosis with less frequent administration than available treatments. 5 Researchers conducted the study using a placebo-controlled design for the first 48 weeks at 183 sites in 26 countries. Patients with RRMS were randomly assigned to receive subcutaneous injection of placebo or 125 μg of peginterferon beta-1a once every 2 weeks or every 4 weeks. The primary end point was annualized relapse rate at 48 weeks. Secondary efficacy end points were the number of new or newly enlarging hyperintense lesions, the proportion of patients who experienced relapse, and the proportion of patients with disability progression at 48 weeks. Of the 1512 patients who were randomly assigned to receive either placebo (n = 500), peginterferon beta-1a every 2 weeks (n = 512), or peginterferon beta-1a every 448 l American Health & Drug Benefits l November 2015 l Vol 8, No 8
2 The Latest Innovations in the Drug Pipeline for Multiple Sclerosis 4 weeks (n = 500), 1332 patients completed 48 weeks of treatment (456 [91%], 438 [88%], 439 [86%] patients, respectively). In the first year of the study, the annualized relapse rate for patients who received peginterferon beta-1a every 2 weeks was lower than that of placebo recipients (0.256 vs 0.397; P =.0007). For those who took peginterferon beta-1a every 4 weeks, the annualized relapse rate was The full results of the 2-year study were published in 2015 and affirm the clinical benefits of the pegylated product. 6 The most common adverse events associated with peginterferon beta-1a were injection-site reactions, flulike symptoms, pyrexia, and headache. All adverse events registered over 1 year were published as percentages of the randomized (not completer) population (N = 1512). Adverse events, including relapse, were reported for 417 (83%) placebo recipients, 481 (94%) patients who took peginterferon beta-1a every 2 weeks, and 472 (94%) patients who took the study drug every 4 weeks. 5 Serious adverse events, such as relapse, pneumonia, and urinary tract infection, occurred in 76 (15%) patients who received placebo, 55 (11%) patients who received peginterferon beta-1a every 2 weeks, and 71 (14%) of those who received the study drug every 4 weeks. 5 Dimethyl Fumarate Dimethyl fumarate (Tecfidera), also manufactured by Biogen, is an oral medication to treat relapsing forms of MS. It is taken twice daily with or without food. Tecfi dera received FDA approval on March 27, 2013, based on the results of 2 global, 2-year, randomized, multicenter, double- blind, placebo-controlled, dosecomparison phase 3 clinical trials (DEFINE and CONFIRM) that demonstrated its effectiveness for long-term treatment of patients with RRMS. 7 In the CONFIRM trial, glatiramer 20 mg (subcutaneous daily injection) was included as a reference comparator. The trial comprised more than 1400 patients with RRMS in 28 countries. Researchers found that patients who received 240 mg of dimethyl fumarate 2 or 3 times daily had a significantly lower relapse rate (0.22 for twice-daily dimethyl fumarate, 0.20 for thrice-daily dimethyl fumarate, 0.29 for glatiramer acetate, 0.40 for placebo) and better neuroradiologic outcomes than placebo recipients. 8 Adverse events that were more common with active treatment than with placebo included flushing and gastrointestinal reactions (with dimethyl fumarate) and injection-related effects (with glatiramer). No malignant neoplasms or opportunistic infections were reported for patients on dimethyl fumarate, but lymphocyte counts decreased with dimethyl fumarate use. 8 In the DEFINE study, more than 1200 patients with KEY POINTS Research and development in the treatment of multiple sclerosis (MS) has been rapid and very active; 95 phase 3 trials are under way, involving a variety of agents. The majority of these clinical trials are being conducted with selective sphingosine-1-phosphate receptor 1 immunomodulators such as laquinimod, ozanimod, ponesimod, and siponimod. It appears that daclizumab, a once-monthly interleukin-2 inhibitor, is leading the race for FDA approval. A decision from the FDA may come by the middle of Late-phase trials are addressing not only MS treatment and relapse prevention but also the sequelae and comorbidities of the disease. RRMS were enrolled at 198 sites in 28 countries. Patients were randomly assigned to receive dimethyl fumarate 240 mg or placebo 2 or 3 times daily. 9 Compared with placebo, both regimens of dimethyl fumarate were associated with a significantly lower relapse rate (27% with twice-daily dimethyl fumarate, 26% with thrice-daily dimethyl fumarate, 46% with placebo) as well as a significantly lower annualized relapse rate, rate of disability progression, and number of lesions observed by magnetic resonance imaging (MRI). In the DEFINE trial, the adverse effects associated with dimethyl fumarate included flushing and gastrointestinal events such as diarrhea, nausea, and upper abdominal pain, as well as decreased lymphocyte counts and elevated levels of aminotransferase in the liver. 9 Using 2 years of pooled data from the DEFINE and CONFIRM trials, researchers affirmed that compared with placebo, dimethyl fumarate reduced the annualized relapse rate (56% reduction; P <.0040), the proportion of patients who experienced relapse (56% reduction; P =.0037), and the time to sustained 12-week progression of disability (78% reduction; P =.0067). 10 The ENDORSE trial was a 3-year extension trial of patients who participated in the DEFINE or CONFIRM studies. 11 According to a press release from the manufacturer, the safety profile of dimethyl fumarate in the EN- DORSE trial was consistent with the favorable findings of the DEFINE and CONFIRM studies and reflected a minimum of 5 years observation per patient. There was no increase in the overall risk for serious infections, including opportunistic infections. 11 Dimethyl fumarate consistently showed long-term efficacy in patients with RRMS who had been treated previously with interferon Vol 8, No 8 l November l American Health & Drug Benefits l 449
3 CLINICAL Table Phase 3 Drug Pipeline for Multiple Sclerosis Nonproprietary name Manufacturer Indication Drug category Estimated FDA submission date Daclizumab highyield Biogen Idec RRMS Interleukin-2 inhibitor April 29, 2015 process and AbbVie Masitinib AB Science PPMS, SPMS Tyrosine kinase inhibitor 2017 Laquinimod Teva and RRMS Immunomodulator a 2017 or beyond b Active Biotech Ponesimod Actelion RRMS Sphingosine-1-phosphate 2018 receptor 1 inhibitor Siponimod Novartis RRMS, PPMS, SPMS Sphingosine-1-phosphate 2017 receptors 1 and 5 inhibitor Ozanimod Celgene RRMS, PPMS, SPMS Sphingosine-1-phosphate 2018 receptors 1 and 5 inhibitor Ocrelizumab Genentech PPMS, SPMS CD20-positive B-cell targeting monoclonal antibody 2016 a Mechanism of action has not been fully elucidated. b New drug application was originally planned in February 2012, but Teva decided not to submit at that time. FDA News. Teva withholds NDA for MS drug laquinimod following FDA talks. February 22, teva-withholds-nda-for-ms-drug-laquinimod-following-fda-talks. PPMS indicates primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis. or glatiramer acetate. 11 Throughout the study period, the annualized relapse rate remained low for patients who received continuous treatment with dimethyl fumarate compared with those who initially received 2 years of placebo in DEFINE and CONFIRM. The annualized relapse rate improved for patients who were switched from placebo in DEFINE and CONFIRM to dimethyl fumarate in ENDORSE, whether they were treatment-naïve or had received interferon or glatiramer acetate. 11 The Phase 3 Pipeline Daclizumab High-Yield Process Biogen is also testing daclizumab (known also as daclizumab high-yield process), a once-monthly interleukin-2 inhibitor intended to reduce annualized relapse rates. The manufacturer, Biogen (and its partner Abb- Vie), submitted a biologic license application in April 2015 (Table), 12 which means that the FDA will likely decide this product s status in the first half of Results from the phase 3 DECIDE clinical trial were recently published in the New England Journal of Medicine. 13 When administered subcutaneously once monthly, daclizumab demonstrated significant reduction of disease activity in people with RRMS in comparison to injections of interferon beta-1a. The 2- to 3-year, phase 3, global, randomized, doubleblind DECIDE study began in May 2010 and ended in July More than 1800 patients with RRMS participated, representing 28 countries. The annualized relapse rate among patients who received daclizumab 150 mg subcutaneously every 4 weeks was 45% lower than for patients treated with interferon beta-1a 30 μg, who served as the control group (P <.0001). Secondary end points included the number of new or newly enlarging lesions as demonstrated by MRI at week 96, the proportion of patients with sustained disability progression, the proportion of relapse-free patients, and the proportion of patients whose physical impact score worsened. 13 The incidence of serious infections was higher for patients treated with daclizumab than for those who received interferon beta-1a (4% vs 2%). Daclizumab recipients had a higher incidence of cutaneous adverse events (37% vs 19%, respectively), serious cutaneous reactions (2% vs <1%), and elevations of liver transaminases greater than 5 times the upper limit of normal (6% vs 3%). There were 4 deaths in the control group and 1 in the daclizumab group, none of which were deemed related to treatment. 13 Another phase 3 long-term extension study for daclizumab is under way, and is scheduled for completion in Masitinib Masitinib, a tyrosine kinase inhibitor, is in late-stage testing for the treatment of patients with secondary and primary progressive MS (PPMS). It is a twice-daily oral medication that targets mast cells and inhibits several biochemical processes. 14 Masitinib also is being tested for use in the treatment of patients with Alzheimer s disease and amyotrophic 450 l American Health & Drug Benefits l November 2015 l Vol 8, No 8
4 The Latest Innovations in the Drug Pipeline for Multiple Sclerosis lateral sclerosis. 15 A communication from the manufacturer, AB Science, indicates that phase 2B testing showed significantly improved MS Functional Composite scores for patients with PPMS and secondary progressive MS (SPMS) compared with scores of the placebo group. A phase 3 trial is currently under way in 600 patients with progressive forms of MS; it is expected to last 96 weeks. 16 This placebo-controlled trial will test masitinib s effect on the MS Functional Composite test, the Expanded Disability Status Scale, and the 54-item Multiple Sclerosis Quality of Life instrument. This study is expected to conclude in 2016, with interim results currently being analyzed. 17 Laquinimod Laquinimod, from Teva and Active Biotech, has demonstrated conflicting late-stage study results. In its phase 2, randomized, placebo-controlled study conducted in 209 people with RRMS, laquinimod demonstrated a 44% decrease in gadolinium (Gd)-enhancing brain lesions over 24 weeks compared with placebo. 18 In a separate 36-week, phase 2b, randomized, placebo- controlled study of 306 patients with RRMS, laquinimod produced reductions of approximately 40% in cumulative Gd-enhancing lesions and T2 lesions compared with placebo. 19 Findings of the phase 3 studies of laquinimod have been difficult to interpret. The 2-year phase 3 ALLEGRO and BRAVO randomized placebo-controlled studies included a combined total of 2400 patients with RRMS. 20,21 The ALLEGRO investigators found that the average annual relapse rate with laquinimod was 23% lower than with placebo. Laquinimod was also associated with a one-third reduction in the progression of disability. 20 However, the BRAVO study provided contradictory results, demonstrating nonsignificant differences (vs placebo) in the annual relapse rate. 21 An analysis of baseline MRI lesion characteristics for the laquinimod and placebo groups revealed that fewer members of the placebo group demonstrated significant lesions compared with that of the patients in the laquinimod group. When this bias was corrected, the annual rate of relapse was significantly lower for the laquinimod group. 22 In the BRAVO study, it appeared that laquinimod had beneficial effects on the progression of disability. 21 In May 2014, the European Medicines Agency declined to approve laquinimod. Teva is moving ahead with additional studies in both RRMS and progressive MS. The CONCERTO study, a phase 3 trial of 2200 patients with RRMS is still under way and not expected to conclude in Ponesimod Ponesimod is an oral investigational drug of the selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator class. Its mechanism of action involves preventing the escape of lymphocytes from lymph nodes, which results in fewer circulating blood lymphocytes and reduced infiltration of lymphocytes into organs affected by disease. Lymphocytes have been implicated in the destruction of myelin on axonal tissue. Actelion conducted a multicenter phase 2 extension study of ponesimod in which 326 patients completed at least 48 weeks of treatment. Results of the trial, published in 2013, showed that active treatment was associated with lower MRI activity and relapse rates. 24 The OPTIMUM phase 3 study is a multicenter, randomized, double-blind, active-controlled comparison trial of ponesimod and teriflunomide in 1100 patients with RRMS. Relapse rate is the primary end point. The 3-year study is expected to conclude in Siponimod Siponimod is a new drug under investigation for SPMS, manufactured by Novartis. It is a tablet taken once daily. Related to fingolimod, siponimod is an oral selective modulator of the sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5. The goal of this increased selectivity is to maintain or improve the efficacy and safety profiles of fingolimod. 25 Like ponesimod, siponimod prevents lymphocytes from leaving lymph nodes. In a phase 2 placebo- controlled study of patients with RRMS, siponimod resulted in significantly lower relapse rates than placebo (0.20 vs 0.58, respectively) and nearly 80% fewer brain lesions as assessed by MRI. 25,26 Common side effects included headache, bradycardia, dizziness, and infections of the nose and throat. 25,26 A new phase 3 study of siponimod in patients with progressive MS is ongoing. The investigators seek to determine the drug s effect on disability progression in these patients. 27 Ozanimod Like siponimod, ozanimod is an S1P receptor modulator that targets receptor subtypes 1 and At the 2015 annual meeting of the American Academy of Neurology, the results of a phase 2 trial of ozanimod for relapsing forms of MS were announced. 29 Ozanimod achieved its primary end point of reduction in MRI brain lesions (86% less activity than placebo). In this placebo-controlled, double-blind trial comprising 258 patients, ozanimod also reduced the annualized relapse rate by 53% compared with placebo (a secondary end point for which it was not statistically powered to detect significance). The safety profile of ozanimod appears to be superior to that of other members of its class. Ninety-eight percent of the patients continued taking the drug for the course of the clinical trial (6 months), which could differentiate this agent from similar drugs. 29 Continued Vol 8, No 8 l November l American Health & Drug Benefits l 451
5 CLINICAL The developing company, Receptos, was purchased by Celgene in July Ozanimod entered 2 phase 3 trials in December 2014 for the treatment of progressive MS. Known as RADIANCE and SUNBEAM, these trials are randomized double-blind studies designed to compare 2 doses of ozanimod with interferon beta-1a. 29 These studies are scheduled to conclude in ,30 Ocrelizumab Ocrelizumab is a CD20-positive monoclonal antibody that targets B-cells, a promising new mechanism of action. The drug is manufactured by Genentech. Results of a phase 2 study showed that 218 patients with RRMS in the intention-to-treat population were found to have 89% fewer Gd-enhancing lesions at week 24 than in the placebo group (P <.0001). 31 In September 2015, Genentech announced the results of its pivotal phase 3 study (dubbed ORATORIO) to evaluate the drug s effectiveness in patients with PPMS. ORATORIO is a multicenter, double-blind, randomized, placebo-controlled trial developed to evaluate the efficacy and safety of ocrelizumab (administered intravenously as two 300-mg infusions 2 weeks apart) in 732 patients with PPMS. 32 Although study results have not yet been released, Genentech reported that ocrelizumab met its primary end point: significant reduction (vs placebo) of the patients clinical disability progression (ie, increase in the Expanded Disability Status Scale), which was demonstrated for 12 weeks or more. Genentech indicated that the drug s safety profile was similar to that of placebo, with the exception of mild to moderate reactions related to the infusion and infusion site. 32 Other Treatments in the Pipeline Natalizumab (Tysabri), produced by Biogen and Elan, has been approved for use in RRMS and is being tested for progressive forms of the disease. 33 Ofatumumab (Arzerra), which is approved for the treatment of patients with chronic lymphocytic leukemia, has shown promise in RMSS. In August 2015, Novartis purchased the rights to ofatumumab (entering phase 3) from GlaxoSmithKline to bolster its MS pipeline. 34 Several phase 3 trials are under way for medications aimed at treating the symptoms or comorbidities of MS. For example, Acthar gel (ACTH) is being tested for its efficacy in addressing fatigue in patients with RRMS. 35 MD1003, a highly concentrated form of biotin, is being tested in Europe for the treatment of patients with progressive MS as well as the optic neuritis associated with MS. 36 Its manufacturer, MedDay, is currently conducting a phase 3 clinical trial for these indications. For progressive MS, interim study results indicated that 13% of the treatment group (vs 0% of the placebo group) demonstrated at least some measurable disability improvement at 12 months of treatment. 37 A small pilot study had indicated a positive effect on disability, prompting the larger phase 3 investigation. 36 In the optic neuritis trial, 105 patients were randomized to receive either MD1003 or placebo. The trial is expected to conclude in The clinical end points are visual clarity and retinal thickness. 36 Conclusion Several manufacturers are testing medications in latestage clinical trials for the treatment of patients with relapsing and progressive forms of MS. The bulk of these agents are selective S1P1 immunomodulators, although other mechanisms of action are being actively investigated. An interleukin-2 agent may be the next medication facing an FDA approval decision. In any case, over the next few years, physicians should be able to choose from several additional medications for treating their patients with MS. n Author Disclosure Statement Ms Radick and Mr Mehr have reported no conflicts of interest. References 1. National Multiple Sclerosis Society. What is MS? org/what-is-ms. Accessed September 28, Biogen Idec. Avonex prescribing information. August com/pdfs/avonex_prescribing_information.pdf. Accessed September 27, Biogen Idec. Biogen Idec s Plegridy (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis. Press release. August 15, media.biogen.com/press-release/multiple-sclerosis-ms/biogen-idecs-plegridy peginterferon-beta-1a-approved-us-treatment. Accessed September 27, Biogen Idec. Plegridy prescribing information. August com/pdfs/plegridy-prescribing-information.pdf. Accessed September 27, Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13: Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler J. 2015;21: Kita M, Fox RJ, Gold R, et al. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther. 2014;36: Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367: Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367: Havrdova E, Hutchinson M, Kurukulasuriya NC. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367: ; and Fox RJ, Miller DH, Phillips JT, et al. Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367: Expert Opin Pharmacother. 2013;14: Biogen Idec. New data from ENDORSE show positive results continued over five years with Tecfidera (dimethyl fumarate) in a wide range of multiple sclerosis patients. Press release. September 11, news/home/ /en/data-endorse-show-positive-results- Continued-Years#.ViD_7vlVhHw. Accessed October 16, Biogen Idec. FDA accepts biologics license application for Zinbryta (daclizumab high-yield process) for treatment of MS. Press release. April 29, l American Health & Drug Benefits l November 2015 l Vol 8, No 8
6 The Latest Innovations in the Drug Pipeline for Multiple Sclerosis Accessed September 27, Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373: ClinicalTrials.gov. Long-term extension study in participants with multiple sclerosis who have completed Study 205MS301 (NCT ) to evaluate the safety and efficacy of BIIB019 (EXTEND). September trials.gov/ct2/show/nct ?no_unk=y&cond=multiple+sclerosis&phase= 2&lup_s=12%2F01%2F2014&lup_e=09%2F29%2F2015&rank=7. Accessed September 29, AB Science. AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%. Press release. RationalisationPipelinevEn.pdf. Accessed October 16, AB Science. Masitinib in progressive forms of multiple sclerosis. July pdf. Accessed September 27, Newman N. Masitinib shows promise in study for treating progressive MS patients. Multiple Sclerosis News Today. July 25, newstoday.com/2015/07/24/masitinib-shows-promise-study-treating-progressivems-patients/. Accessed October 16, Comi G, Pulizzi A, Rovaris M, et al; LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsingremitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet. 2008;371: Comi G, Abramsky O, Arbizu T, et al; LAQ/5063 Study Group. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week doubleblind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010;16: Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366: Vollmer TL, Sorensen PS, Selmaj K, et al; BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261: MultipleSclerosis.net. Laquimod for MS research/laquinimod/. Accessed October 16, Multiple Sclerosis Society. Laquinimod turned down for a European licence. June 18, Accessed October 16, Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014; 85: ClinicalTrials.gov. Oral ponesimod versus teriflunomide in relapsing multiple sclerosis (OPTIMUM). August 26, ?term=ponesimod&rank=4. Accessed October 16, Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsingremitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet. 2013;12: ClinicalTrials.gov. Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND). August 18, www. clinicaltrials.gov/ct2/show/nct ?no_unk=y&cond=multiple+sclerosis& phase=2&lup_s=12%2f01%2f2014&lup_e=09%2f29%2f2015&rank=21. Accessed September 27, Science Daily. Multiple sclerosis drug candidate shows new promise. September 19, Accessed October 12, Moore C. Celgene to acquire Receptos, advancing leadership in immuneinflammatory diseases such as MS and IBD. Multiple Sclerosis News Today. July 17, Accessed September 25, ClinicalTrials.gov. Efficacy and safety study of RPC1063 in relapsing multiple sclerosis (Radiance Study). April 14, ?no_unk=Y&cond=multiple+sclerosis&phase=2&lup_s=12%2F01% 2F2014&lup_e=09%2F29%2F2015&rank=55. Accessed September 27, Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378: Silva P. Could Genentech s ocrelizumab become the first effective primary progressive MS therapy? Multiple Sclerosis News Today. September 29, Accessed September 29, ClinicalTrials.gov. Natalizumab and multiple sclerosis. October 18, 2015.www. clinicaltrials.gov/ct2/results?term=natalizumab+and+multiple+sclerosis&recr=& rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=& cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=1& phase=2&rcv_s=&rcv_e=&lup_s=&lup_e=. Accessed October 18, Novartis. Novartis acquires all remaining rights to GSK s ofatumumab to develop treatments for MS and other autoimmune indications. Press release. August 21, Accessed September 29, ClinicalTrials.gov. ACTH for fatigue in multiple sclerosis patients. May 13, sclerosis&phase=2&lup_s=12%2f01%2f2014&lup_e=09%2f29%2f 2015&rank=10. Accessed September 29, Multiple Sclerosis Society. MD Accessed September 28, Tourbah A, Lebrun-Frenay C, Edan G. MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial. Presented at the 2015 annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis; October 7-10, 2015; Barcelona, Spain. onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/116698/tourbah.ayman. md1003.(high.doses.of.biotin).in.progressive.multiple.sclerosis.html?f=m3. Accessed October 19, Vol 8, No 8 l November l American Health & Drug Benefits l 453
MAY 2017 RESEARCH U P D A T E
MAY 2017 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Michelle Fabian, MD and Stephen Krieger, MD Includes additional material by Margaret M. McCormick, RN, BSN, MSCN Reviewed
More informationAubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
Aubagio (teriflunomide tablets) Policy Number: 5.01.614 Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Alemtuzumab, dimethyl fumarate, laquinimod and teriflunomide for the treatment of relapsing forms of multiple
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationDimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials
Dimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract Treatment options for multiple
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationMAY 2018 RESEARCH U P D A T E
MAY 2018 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Tom Garry with Stephen Krieger, MD and Michelle Fabian, MD Reviewed by Jack Burks, MD Edited by Susan Courtney The 2018
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 7/2018 Origination: 8/2015 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Lemtrada
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationAdvances in Immunomodulatory Therapy for Multiple Sclerosis
Advances in Immunomodulatory Therapy for Multiple Sclerosis Sona Narula, MD Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Abstract Significant research has been directed toward the development
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationS.E.A.R.C.H. SM Patient Workbook
S.E.A.R.C.H. SM Patient Workbook How to S.E.A.R.C.H. SM for the Right MS Therapy For You! What is S.E.A.R.C.H. SM? The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by
More informationThe Latest Therapies for MS: Weighing Respective Benefits and Risks
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/frontlines-multiple-sclerosis/the-latest-therapies-for-ms-weighingrespective-benefits-and-risks/9639/
More informationSupplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values
Supplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Detailed Input Tables Table A.1: Annual Probability
More informationApproved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy. Date approved: 06/21/17
Integrated Healthcare Services and Criteria Document: Reference #: PC/B016 Page: 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.CPA.331 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationClinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 04.01.17 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.PHAR.256 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at
More informationTechnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320
Dimethyl fumarate ate for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 NICE 2018. All rights reserved. Subject to Notice
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationCladribine. Spirella Building, Letchworth, SG6 4ET reg charity no
Cladribine Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cladribine Date of issue: February 2009 Contents Section Page 1. Introduction 1 2. How cladribine
More information2018 ECTRIMS Data Review Call. October 2018
2018 ECTRIMS Data Review Call October 2018 TG Therapeutics Michael S. Weiss, CEO Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B016 Page: 1 of 4 and Therapeutics Quality PRODUCT APPLICATIO: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne
More informationIR Thematic Call on Multiple Sclerosis
Teresa, Multiple Sclerosis, United States IR Thematic Call on Multiple Sclerosis October 3 rd, 2013 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationMultiple Sclerosis Agents
Multiple Sclerosis Agents Policy Number: 5.01.614 Last Review: 09/2018 Origination: 07/2014 Next Review: 09/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationTHE EXPANDING ARMAMENTARIUM OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES: MULTIPLE SCLEROSIS OVERVIEW II: CLINICAL ADVANCES
THE EXPANDING ARMAMENTARIUM OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES: MULTIPLE SCLEROSIS OVERVIEW II: CLINICAL ADVANCES Brief Overview Scott Newsome It is extremely important for clinicians treating
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationClinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 COPAXONE 20 mg/ml, solution for injection, pre-filled syringe B/28 (CIP code: 363 840-1) Applicant: SANOFI-AVENTIS
More informationMultiple Sclerosis: KOL Insight 2016
Multiple Sclerosis: KOL Insight 2016 Multiple Sclerosis: KOL Insight 2016 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. Multiple Sclerosis Agents Ampyra Aubagio Avonex Betaseron Copaxone Extavia Gilenya Glatopa Plegridy Rebif Tysabri
More informationSESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY
SESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY Bruno C. Musch, MD PhD Baveno, Italy November 30th, 2013 DISCLOSURE OF INTEREST Dr.Musch is currently Medical Director in GENENTECH/Roche,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) GLATIRAMER ACETATE (GLATECT PENDOPHARM) Indication: Relapsing-Remitting Multiple Sclerosis RECOMMENDATION: The CADTH
More informationDisclosures and Acknowledgments
214 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Dallas, Texas DX1 Disability Progression in Multiple Sclerosis
More informationA BS TR AC T. n engl j med 367;12 nejm.org september 20,
The new england journal of medicine established in 1812 september 20, 2012 vol. 367 no. 12 -Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis Robert J. Fox, M.D., David H. Miller,
More informationMedication Prior Authorization Form
(Orelizumab) Policy Number: 1073 Policy History Approve Date: 05/19/2017 Effective Date: 05/19/2017 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for
More informationRESEARCH/CLINICAL UPDATE
National Multiple Sclerosis Society 733 Third Avenue New York, New York 10017-3288 Tel +1 212.986.3240 Fax +1 212.986.7981 E-mail nat@nmss.org nationalmssociety.org October 30, 2007 RESEARCH/CLINICAL UPDATE
More informationExtending Our Leadership Position in Multiple Sclerosis. December 12, 2018
Extending Our Leadership Position in Multiple Sclerosis December 12, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: our strategy
More informationMS Injectable Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: MS Injectable Drugs Page: 1 of 5 Last Review Date: November 30, 2018 MS Injectable Drugs Description
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab),
More informationMycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study
Received: 20.6.2010 Accepted: 5.8.2010 Original Article Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study Masoud
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationRoche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis
Investor Update Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis Data presentations will
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More informationA look into the future - International Progressive MS Alliance. Dr Dhia Chandraratna Head of Research, MSIF
A look into the future - International Progressive MS Alliance Dr Dhia Chandraratna Head of Research, MSIF Neurologist: Accumulation of disability Gradual change over time Imager: Defining Progressive
More informationMedia Release. Basel, 14 June 2018
Media Release Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive
More informationEvidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Evidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Produced by CRD and CHE Technology Assessment Group Authors Gill Norman, Research Fellow, CRD Stephen
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Tysabri, (natalizumab), Lemtrada (alemtuzumab), Page 1 of 21 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Tysabri (natalizumab), Lemtrada (alemtuzumab),
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More information1 New MS treatments and updates on established treatments
Teaching Course 1 Disease modifying treatment Chairs: R.J. Fox (Cleveland, US) L. Kappos (Basel, CH) 1 New MS treatments and updates on established treatments R.J. Fox (Cleveland, US) 2 Assessing and mitigating
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationDrug development and evaluation with small clinical Trials from the regulatory point of view
Drug development and evaluation with small clinical Trials from the regulatory point of view Harumasa Nakamura, M.D. Deputy Review Director Office of New Drug III Pharmaceuticals and Medical Devices Agency
More informationThe MS Disease- Modifying Medications. General information
The MS Disease- Modifying Medications General information Current as of April 2013. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationDisease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value
Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Response to Public Comments on Draft Evidence Report January 26, 2017 Institute
More informationACTELION TRANSFORMATION ON THE WAY. Jean-Paul Clozel Chief Executive Officer. Copyright 2016 Actelion Pharmaceuticals Ltd
ACTELION 2015 2020 TRANSFORMATION ON THE WAY Jean-Paul Clozel Chief Executive Officer Copyright The following information contains certain forward-looking statements, relating to the company s business,
More informationInvestor Update. Basel, 14 June 2018
Investor Update Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationOptions for Wheeled Mobility Resource Detectives Program Achievements MSAA. Summer Research UPDATE
Options for Wheeled Mobility Resource Detectives Program Achievements MSAA Summer 2009 MS Research UPDATE 2009 Volunteering Opportunities from MSAA Volunteering with MSAA offers multiple opportunities
More informationPresentation Overview
Best Practices in the Treatment and Management of Multiple Sclerosis The Payer s Perspective Gary M. Owens, MD NAMCP April 22, 2016 1 Presentation Overview MS background and disease state review Diagnosing
More informationTechnology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303
Teriflunomide for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303 NICE 2018. All rights reserved. Subject to Notice of
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationJEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 4, 2015 VINCENT J. ANGOTTI, CHIEF OPERATING OFFICER
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 4, 2015 VINCENT J. ANGOTTI, CHIEF OPERATING OFFICER COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR LANGUAGE These slides and the accompanying
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationChallenges in randomized controlled trials and emerging multiple sclerosis therapeutics
Neurosci Bull December 1, 2015, 31(6): 745 754. http://www.neurosci.cn DOI: 10.1007/s12264-015-1560-6 745 Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics DeRen Huang
More informationThe Medical Letter. on Drugs and Therapeutics. Volume 58 June 6, Drugs for Multiple Sclerosis... p 71. Important Copyright Message
The Medical Letter on Drugs and Therapeutics Volume 58 ISSUE ISSUE No. 1433 1496 Volume 56 IN THIS ISSUE Drugs for Multiple Sclerosis... p 71 Important Copyright Message FORWARDING OR COPYING IS A VIOLATION
More informationECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
EAN GUIDELINES/CME ARTICLE ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X. Montalban a, R. Gold b, A. J. Thompson c, S. Otero-Romero a,d, M. P. Amato e, D. Chandraratna
More informationMultiple sclerosis (MS) is a chronic, unpredictable
Prescription Utilization by Multiple Sclerosis Patients in the United States Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; Stacey Ruf, PhD; and John A. Szychowski, AAS, BS Multiple sclerosis
More informationThe Weekly Mortar & Pestle
The Weekly Mortar & Pestle A Publication of Walgreens Health Initiatives January 24, 2008 A publication created especially for our clients and associates, delivering up-to-date information about brand-name
More informationAntibody therapy of multiple sclerosis Prof. Alastair Compston Dr. Alasdair Coles
Antibody therapy of multiple sclerosis & Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, U.K. 1 The story of multiple sclerosis: 1838-1993 2 The symptoms of
More informationMultiple Sclerosis Landscape: Is there a paradigm shift?
Multiple Sclerosis Landscape: Is there a paradigm shift? Christine Blazynski, PhD Chief Science Officer and Senior Vice President, New Product Development,, Inc. The standard of care treatment for multiple
More informationHelen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester
Helen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester helen.pervanas@mcphs.edu Objectives Describe the pathophysiology, diagnosis and prognosis of MS Discuss disease
More informationFORUM IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties
FORUM IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties Jagadeesh Bayry, Hans-Peter Hartung, Srini V Kaveri To cite this version: Jagadeesh Bayry, Hans-Peter Hartung, Srini V
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.45 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationScottish Medicines Consortium
Scottish Medicines Consortium interferon alfa 2b (Viraferon and Intron A* ) 18 million IU, solution for injection, multidose pen in combination with ribavirin (Rebetol ) capsules 200 mg No. (258/06) Schering
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report October 2014 Drug Teriflunomide (Aubagio) (14 mg film-coated tablet) Indication Teriflunomide is indicated as monotherapy for the treatment of patients
More informationTITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE
TITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE JULY 23, 2014 Forward-Looking Statements This presentation contains forward-looking statements, including statements about
More informationUntil two decades ago, steroids were the
CMAJ Review CME Drug therapy for multiple sclerosis Eleonora Tavazzi MD, Marco Rovaris MD, Loredana La Mantia MD Until two decades ago, steroids were the only available treatment for multiple sclerosis
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationEmerging Therapies for the Management of Multiple Sclerosis
Clinical Medicine Insights: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Emerging Therapies for the Management of Multiple Sclerosis
More informationCD56 bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS
CD56 bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS J. Elkins, MD J. Sheridan, PhD L. Amaravadi, PhD K. Riester, MPH K. Selmaj, MD, PhD B. Bielekova, MD E. Parr, PhD
More informationReview of week-24 results
Review of week-24 results GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of in patients with relapsing remitting
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More information